BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
What does it do?
BioNTech is a German biotech company best known for co-creating the Pfizer-BioNTech COVID-19 vaccine — one of the first mRNA vaccines ever approved for public use. Think of mRNA as a set of temporary instructions you inject into the body that teach your immune system to fight a specific threat. Beyond COVID, BioNTech is now using that same mRNA technology to try to fight cancer, developing experimental drugs targeting lung cancer, breast cancer, and other tumors. They are essentially trying to turn the immune system into a cancer-killing machine.
BioNTech proved that mRNA technology works at massive scale, which was a landmark moment for medicine — and now they are betting that same platform can crack one of the hardest problems in healthcare: cancer treatment. Investors are watching closely because if even one of their cancer drugs succeeds in late-stage trials, it could open an enormous new market worth tens of billions of dollars. The company also sits on a large cash reserve built from COVID vaccine profits, giving it an unusual safety net compared to most early-stage biotechs.
How does it make money?
BioNTech makes most of its money from royalties and profit-sharing on the Comirnaty COVID-19 vaccine, which is sold globally through its partnership with Pfizer. In the latest financial year, the company brought in $2.9 billion in revenue, a small step up from $2.8 billion the prior year, but it still posted a net loss of $1.1 billion as it pours money into cancer research and clinical trials. The gross profit figure being effectively zero signals that after manufacturing and partner costs, the COVID vaccine business alone is not yet covering the company's heavy investment in its cancer pipeline.
Why do investors care?
The core investment story is a pivot: BioNTech wants to transition from a one-hit COVID vaccine company into a full cancer immunotherapy powerhouse. They have multiple cancer drugs in Phase III trials — the last major testing stage before potential approval — including treatments for lung cancer and breast cancer, which are among the most common cancers worldwide. If one or more of these drugs gets approved in the next few years, BioNTech could unlock a completely new and recurring revenue stream that does not depend on annual COVID booster demand. The upside is enormous, but so is the scientific risk.
Deep Dive
MemberA full investor briefing on BioNTech SE — history, leadership, risks, and outlook.